Q-omics provides the consensus-scored CXCL17 profile across patient tissues and cancer cell-line models. CXCL17 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, CXCL17 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, CXCL17 protein abundance shows 16,098 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight PAAD, HNSC, and LSCC as cancer lineages where CXCL17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CXCL17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CXCL17 survival associations across molecular data types. CXCL17 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CXCL17 RNA expression–survival associations across cancer types. High CXCL17 expression shows unfavorable associations in PAAD and STAD, but favorable associations in LUAD, DLBC, HNSC and LUSC. The PAAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for CXCL17 RNA expression.
This table summarizes CXCL17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for CXCL17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CXCL17 shows lower tumor expression in HNSC, LUSC, LUAD and STAD and higher tumor expression in THCA and COAD. The HNSC box plot shows higher CXCL17 RNA expression in normal versus tumor tissue (log2 FC = −3.028, t-test p < 0.001).
This table shows molecular features associated with CXCL17 in patient tissues and cancer cell lines. In patient samples, CXCL17 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CXCL17 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_NSCLC_LUAD.
